Compare SPFI & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPFI | ZVRA |
|---|---|---|
| Founded | 1941 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 725.9M | 653.2M |
| IPO Year | 2019 | 2015 |
| Metric | SPFI | ZVRA |
|---|---|---|
| Price | $40.49 | $10.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $46.00 | $23.00 |
| AVG Volume (30 Days) | 72.7K | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | 17.81 | ★ 159.21 |
| EPS | ★ 0.85 | 0.60 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $22.65 | $37.27 |
| Revenue Next Year | $9.40 | $53.42 |
| P/E Ratio | $47.27 | ★ $19.15 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $33.66 | $7.16 |
| 52 Week High | $45.09 | $13.16 |
| Indicator | SPFI | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.29 | 52.90 |
| Support Level | $38.19 | $8.26 |
| Resistance Level | $41.87 | $11.07 |
| Average True Range (ATR) | 0.87 | 0.57 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 61.32 | 44.50 |
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.